Finland's Forendo Attracts Big Pharma For Liver Disease R&D
Deal To Boost Novartis's Liver Disease Efforts
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
You may also be interested in...
Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.
Novartis thinks tropifexor may prove to be best-in-class FXR agonist, while Pfizer notes the complementary activity of its ACC and DGAT2 inhibitors. Their NASH trial collaboration is heading toward a Phase II launch in 2020.
Deal for preclinical asset adds an anti-fibrotic mechanism to Novartis’ NASH program. Pliant produced preclinical data showing strong anti-fibrotic effect.